India to receive its second homegrown vaccine by Biological-E

Biological-E, India’s oldest private vaccine maker, is currently engaged in Phase 3 clinical trials of their own version of a COVID-19 vaccine, after promising results in Phase 1 and Phase 2, which will soon become India’s second domestically developed vaccine, after Bharat Biotech’s “Covaxin”. The government of India has already signed a deal with the company for 300mn vaccines, for a sum of INR 15bn (USD 205mn).

The company has received support from the government to develop the vaccine, as the Department of Biotechnology has provided both financial and technical support through INR 10mn grant-in-aid, and by part partnering with Biological-E to conduct all animal challenge and assay studies through its Research Institute Translational Health Science Technology Institute (THSTI), Faridabad.

Download our free webinar recording - "India's Budget 2021-2022 | Economy vs Finance in a Pandemic". Take a look at our full list of archived webinars here.